March 2026
Ibogaine
What March 2026's 5 new studies found, synthesized from the papers below. All Ibogaine research →
The synthesis
Synthesized from 5 studies in the library · AI-generated, grounded in the abstracts below
Found by searching the library for Ibogaine, iboga, noribogaine, then ranked by relevance.
Research on ibogaine in March 2026 shows that ibogaine and its derivative oxa-noribogaine reduce alcohol consumption in rats and are associated with long-term PTSD symptom improvement in veterans, with evidence of brain network reorganization. However, ibogaine did not prevent cocaine relapse in rats, and historical and safety concerns regarding plant authenticity were highlighted. The evidence is limited by small sample sizes, preclinical models, and observational designs.
Evidence by study
Direction is which way each study's own result points, not our rating of the study.
What the directions mean
- Supports:
- the study found the intervention worked, or its hypothesis held.
- Opposes:
- it found the opposite, no benefit or a harm.
- No effect:
- no significant difference either way.
- Mixed:
- effects in both directions within the same study.
- Unclear:
- the abstract does not report a direction.
| Study | Design | Sample size | Direction | Finding |
|---|---|---|---|---|
| Oxa-noribogaine reduces alcohol drinking through aversion learning and by altering glutamatergic activity in the mPFC 2026 | preclinical (rat model) | Supports | Oxa-noribogaine reduced alcohol consumption and relapse-like drinking in rats, with efficacy matching ibogaine and without motor or cardiac side effects. | |
| Ibogaine is associated with reorganization of high-beta brain networks in veterans with post-traumatic stress disorder 2026 | observational | 30 | Supports | A single dose of ibogaine was associated with long-term PTSD symptom improvement and reorganization of high-beta brain networks, with effects replicated in an independent dataset. |
| The long roots of ibogaine: A journey from plant to pharmaceutical 2026 | historical review | Unclear | The review highlights colonial and commercial histories of ibogaine development prior to the 1960s, emphasizing power dynamics and biopiracy. | |
| Psilocybin and Ibogaine in Cocaine‐Seeking: Extinction Enhancement Without Relapse Prevention 2026 | preclinical (rat model) | Mixed | Ibogaine enhanced extinction of cocaine-seeking behavior but did not prevent cue-induced reinstatement (relapse), with no effect on locomotor activity or anxiety. | |
| Development and optimization of a reliable HPLC-MS method for the identification of Tabernanthe iboga and its differentiation from toxic look-alikes 2026 | method development | Unclear | An HPLC-MS method was developed to differentiate Tabernanthe iboga from toxic look-alikes, addressing safety concerns in ibogaine clinics. |
Oxa-noribogaine reduced alcohol consumption and relapse-like drinking in rats, with efficacy matching ibogaine and without motor or cardiac side effects.
preclinical (rat model)
A single dose of ibogaine was associated with long-term PTSD symptom improvement and reorganization of high-beta brain networks, with effects replicated in an independent dataset.
observational Sample size: 30
The review highlights colonial and commercial histories of ibogaine development prior to the 1960s, emphasizing power dynamics and biopiracy.
historical review
Ibogaine enhanced extinction of cocaine-seeking behavior but did not prevent cue-induced reinstatement (relapse), with no effect on locomotor activity or anxiety.
preclinical (rat model)
An HPLC-MS method was developed to differentiate Tabernanthe iboga from toxic look-alikes, addressing safety concerns in ibogaine clinics.
method development
Points of agreement
- Ibogaine and its derivatives show potential for reducing substance use and PTSD symptoms in preclinical and observational studies.
- Brain network changes (e.g., high-beta shifts) are associated with ibogaine treatment effects.
- Safety and quality control of ibogaine sources are recognized as important issues.
Conflicts
- Ibogaine reduced alcohol consumption and PTSD symptoms but did not prevent cocaine relapse in rats.
- The historical review emphasizes colonial exploitation, while other studies focus on therapeutic potential without addressing these ethical dimensions.
Gaps
- No randomized controlled trials in humans were reported.
- Durability of effects beyond one month in humans is not well studied.
- Effects in diverse populations (e.g., non-veterans, women) are lacking.
- Optimal dosing and long-term safety of ibogaine and its derivatives remain unclear.
- The role of context (set and setting) in ibogaine treatment is not addressed in these studies.